Human cytomegalovirus (CMV) is one of the most important viral pathogens affecting
hematopoietic stem cell transplant (HSCT) and solid organ transplant (SOT) recipients …

The study of human cytomegalovirus (HCMV) antiviral drug resistance has enhanced
knowledge of the virological targets and the mechanisms of antiviral activity. The currently …

This editorial summarizes recent developments in the management of ganciclovir-resistant
human cytomegalovirus (HCMV) infections. All current drugs available for systemic …

Resistance of cytomegalovirus (CMV) to antiviral agents is a well-recognized phenomenon
that has been observed in the laboratory and in the clinical setting. Infections caused by …

This review discusses the management of resistant cytomegalovirus and prevention
strategies for fatal therapy failures. Five drugs, ganciclovir/valganciclovir, cidofovir, foscarnet …

JM Iwasenko, GM Scott, Z. Naing, AR Glanville, WD Rawlinson. Diversity of antiviral‐
resistant human cytomegalovirus in heart and lung transplant recipients. Transpl Infect Dis …

Despite advances in preventive strategies, cytomegalovirus (CMV) infection remains a major
complication in solid organ and hematopoietic cell transplant recipients. CMV infection may …

Technical advancements can enhance the accurate and timely genotypic detection of drug
resistance. Antivirals undergoing clinical trial offer the prospect of new viral targets and drug …

Infection with cytomegalovirus (CMV) remains a significant cause of morbidity and mortality
among hematopoietic cell transplant (HCT) recipients. We describe two pediatric HCT …

Antiviral agents are commonly used for cytomegalovirus (CMV) prophylaxis or therapy after
solid organ transplantation. Until recently, the detection of drug‐resistant CMV in this setting …